Larotrectinib
Cat. No.:YN380067
| 产品名称: | Larotrectinib |
| CAS No.: | 1223403-58-4 |
| Chemical Name: | (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-1-pyrrolidinecarboxamide |
| Synonyms: | LOXO-101; ARRY-470 |
| 分子量: | 428.44 |
| 分子式: | C₂₁H₂₂F₂N₆O₂ |
| SMILES: | O=C(N1C[C@@H](O)CC1)NC2=C3N=C(N4[C@@H](C5=CC(F)=CC=C5F)CCC4)C=CN3N=C2 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Larotrectinib (LOXO-101) 是一种 ATP 竞争性的、口服选择性抑制剂,对原肌凝蛋白相关激酶(TRK)家族受体的三个亚型 (TRKA,B 和C) 具有纳摩尔级别的 50% 抑制浓度。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Doebele, R.C., Davis, L.E., Vaishnavi, A., et al.An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101Cancer Discov.5(10),1049-1057(2015)